Halozyme To Host First Quarter 2022 Financial Results Webcast and Conference Call

<br /> Halozyme To Host First Quarter 2022 Financial Results Webcast and Conference Call<br />

PR Newswire

SAN DIEGO

,

May 3, 2022

/PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2022 on

May 10

at

4:30 p.m. ET

/

1:30 p.m. PT

. Dr.

Helen Torley

, president, and chief executive officer, will lead the call. On the same date, Halozyme will release financial results for the first quarter ended

March 31, 2022

, following the close of trading.

To register for this conference call, please use this link:

https://events.q4inc.com/attendee/321325561

. After registering, you will receive an email confirmation that includes dial in details and unique conference call codes for entry. Registration is open through the live call. However, to ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call.

The call will be webcast live through the ”

Investors

” section of Halozyme’s corporate website and a recording will be made available following the close of the call. To access the webcast and additional documents related to the call, please visit the

Investors page

of

www.halozyme.com

approximately 15 minutes prior to the call to register, download and install any necessary audio software. A telephone replay will be available for two weeks after the call by dialing (800) 770-2030 (domestic callers) or (416) 621-4642 (international callers) using replay ID number 89853.

About Halozyme

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients’ lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme’s commercially-validated solution has touched more than 600,000 patient lives in post-marketing use via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme’s proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare and Chugai Pharmaceutical. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company’s partners make progress developing and commercializing their products being developed using ENHANZE®. Halozyme is headquartered in San Diego. For more information visit

Halozyme.com

and connect with us on

LinkedIn

and

Twitter

.